Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain

Status:
Completed

Trial end date:
2011-03-22

Target enrollment:

Participant gender:

The primary objective of the study is to evaluate the safety of single doses of oral naldemedine in adults physically dependent on opioids.

Phase 2

Shionogi

Analgesics, Opioid